Scancell Holdings PLC (AIM
CLP, OTC
CNLF) has reported what it described as 'strong' phase II results for its experimental immunotherapy, iSCIB1+, showing a marked improvement in outcomes for patients with late-stage melanoma when added to standard treatments. The UK-based life sciences group announced that its SCOPE trial, which is assessing the Immunobody DNA-based therapy in combination with established checkpoint inhibitors, showed an overall response rate of 69% in patients with a specific genetic marker.
